Research and Markets: Assessment of the Impact of Glucophages Patent Expiry on Merck KGaAs Therapeutic Focus.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com) has announced the addition of PharmaVitae 2004: Merck KGaA Global & US Analysis to their offering. This analysis examines the market position and future outlook for Merck KGaA. The profile encompasses global and US specific company strategy, portfolio and pipeline analysis and assessment of financial performance, with US, rest of world and global forecasts for key drugs to 2010. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. Reasons to Purchase -Assess the continued impact of Glucophages patent expiry on Merck KGaAs therapeutic focus -Benchmark Merck KGaAs performance against key rivals in the ethical pharmaceutical sector -Understand the potential of Merck KGaAs developing oncology portfolio TABLE OF CONTENTS CHAPTER 1 EXECUTIVE SUMMARY 4 Key findings 4 Current positioning: competitive outlook 2003 5 Future performance: growth drivers and resistors 2004-10 6 Evolution in therapeutic focus, 2003-10 8 Key issues facing Merck KGaA, 2004-10 9 Strategic outlook 11 CHAPTER 2 GLOBAL COMPANY STRATEGY 19 Introduction to Merck KGaA 20 Assessment of strategic position 20 Strengths 20 Weaknesses 21 Opportunities 22 Threats 23 Therapeutic foci 24 R&D productivity 26 Development opportunities 27 Organic growth 27 Partnerships/licensing 27 Mergers and acquisitions 28 Geographical expansion 29 Implications of financial position 31 CHAPTER 3 GLOBAL PORTFOLIO AND PIPELINE ANALYSIS 32 Therapy area focus in 2003 33 Business development by therapy area 34 Forecast revenue stream, 2004-10 37 Therapy area forecasts to 2010 37 Diabetes & endocrinology 1. the study of hormones and the endocrine system. 2. a medical specialty concerned with the diagnosis and treatment of disorders of the endocrine system. en·do·cri·nol·o·gy (  n franchise 39 Marketed products 39 R&D compounds 44 Diabetes & endocrinology portfolio sales forecasts and forecast revenue growth 45 Cardiovascular franchise 46 Marketed products 46 R&D compounds 51 Cardiovascular portfolio sales forecasts and forecast revenue growth 55 Respiratory franchise 56 Marketed products 56 R&D compounds 60 Respiratory portfolio sales forecasts and forecast revenue growth 60 Oncology franchise 61 R&D compounds 61 Oncology portfolio sales forecasts and forecast revenue growth 72 Other products 72 Marketed products 73 R&D compounds 79 Other products sales forecasts and forecast revenue growth 83 Generics business 84 CHAPTER 4 US STRATEGY, PORTFOLIO AND PIPELINE 85 US company strategy 86 Introduction to Merck KGaA's presence in the US 86 US product sourcing strategy 86 US portfolio and pipeline analysis 87 US therapy area focus in 2003 87 US business development by therapy area 89 Forecast US revenue stream, 2004-10 90 Respiratory portfolio US sales forecasts and forecast revenue growth 92 Diabetes & endocrinology portfolio US sales forecasts and forecast revenue growth 93 Cardiovascular portfolio US sales forecasts and forecast revenue growth 95 Oncology portfolio US sales forecasts and forecast revenue growth 96 Other portfolio US sales forecasts and forecast revenue growth 97 Generics business 98 CHAPTER 5 CORPORATE DEVELOPMENT 99 Financial position, 2002-03 100 Profitability, 1999-2003 100 Revenue growth 100 Cost structure 102 Profitabilty 103 Liquidity, 1999-2003 104 2003 performance benchmarking 105 Business model clustering according to 2003 cost ratios 105 2003 growth and investment momentum 107 Key events shaping corporate activity, 1999-2003 109 Merger and acquisition activity 109 Corporate alliances and deals 110 CHAPTER 6 APPENDIX: SUPPORTING DATA 115 Financial data 115 Exchange rates 115 Methodology for therapy area forecasting 116 For more information visit http://www.researchandmarkets.com/reports/c7630 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion